About Nucleus Radiopharma
Nucleus Radiopharma is a private company based in Palo Alto, California, incorporated in 2022 in Delaware. It has reported $72,099,956 raised in two offerings on Form D since April 2024. Its chief executive is Charles Conroy.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Sep 15, 2023 | Apr 11, 2024 | $66,099,956fully sold | 12 | $5.5M | Equity, Preferred Stock can convert to underlying shares of Common Stock.Rule 506(b) | Form D ↗ |
| Oct 4, 2022 | Apr 11, 2024 | $6,000,000fully sold | 3 | $2.0M | Equity, Preferred Stock can convert to underlying shares of Common Stock.Rule 506(b) | Form D ↗ |
| Total, two offerings | $72,099,956 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Nucleus Radiopharma's Form D filed Apr 11, 2024.
TR
Tyrell Rivers
Director
MW
Mary Kate Wold
Director
MR
Michael Rossi
Director
NS
Norman Sharpless
Director
CM
Chris McDonald
Director
MN
Manu Nair
Director
JB
Justin Butler
Director
CC
Charles Conroy
Chief Executive Officer and director